Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
ObjectiveNeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.DesignParallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After indu...
Saved in:
| Published in | Gut Vol. 68; no. 1; pp. 40 - 48 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BMJ Publishing Group LTD
01.01.2019
BMJ Publishing Group |
| Series | Original article |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | ObjectiveNeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.DesignParallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.Results247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn’s Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.ConclusionsPF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.Trial registration numberNCT01287897 and NCT01345318. |
|---|---|
| AbstractList | Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.OBJECTIVENeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.DESIGNParallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn's Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.RESULTS247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn's Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.PF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.CONCLUSIONSPF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.NCT01287897 and NCT01345318.TRIAL REGISTRATION NUMBERNCT01287897 and NCT01345318. ObjectiveNeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.DesignParallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.Results247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn’s Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.ConclusionsPF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.Trial registration numberNCT01287897 and NCT01345318. Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported. Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. : 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. : PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up. 247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn's Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis. PF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development. NCT01287897 and NCT01345318. |
| Author | Fraser, Gerald Rogler, Gerhard Leong, Rupert W Panaccione, Remo Maguire, Mary K Cataldi, Fabio Li, Cheryl Kohn, Anna Rath, Natalie Beebe, Jean Danese, Silvio Schreiber, Stefan Banerjee, Anindita Hellstern, Paul Comer, Gail M Desreumaux, Pierre Vermeire, Séverine |
| AuthorAffiliation | 6 Division of Gastroenterology, Rabin Medical Center , University of Tel-Aviv , Petah Tikva , Israel 10 Formerly of Worldwide Research and Development , Pfizer Inc , Cambridge , Massachusetts , USA 11 Worldwide Research and Development , Pfizer Inc , Cambridge , Massachusetts , USA 13 Department of Medicine I , Christian-Albrechts-University and University Hospital Schleswig-Holstein , Kiel , Germany 12 Worldwide Research and Development , Pfizer Inc , Collegeville , Pennsylvania , USA 9 Inflammatory Bowel Diseases Service , Concord Hospital , Sydney , New South Wales , Australia 2 Department of Gastroenterology , University Hospitals Leuven , Leuven , Belgium 4 Inflammatory Bowel Disease Clinic , University of Calgary , Calgary , Canada 7 UOC Gastroenterologia , AO San Camillo Forlanini , Rome , Italy 8 Lille University School of Medicine , University of Lille, Inserm U995 , Lille , France 1 Gastrointestinal Immunopathology Lab and IBD Unit , Humanitas Clinical and Research Center and Humanitas |
| AuthorAffiliation_xml | – name: 4 Inflammatory Bowel Disease Clinic , University of Calgary , Calgary , Canada – name: 11 Worldwide Research and Development , Pfizer Inc , Cambridge , Massachusetts , USA – name: 8 Lille University School of Medicine , University of Lille, Inserm U995 , Lille , France – name: 10 Formerly of Worldwide Research and Development , Pfizer Inc , Cambridge , Massachusetts , USA – name: 2 Department of Gastroenterology , University Hospitals Leuven , Leuven , Belgium – name: 9 Inflammatory Bowel Diseases Service , Concord Hospital , Sydney , New South Wales , Australia – name: 12 Worldwide Research and Development , Pfizer Inc , Collegeville , Pennsylvania , USA – name: 3 Nature Coast Clinical Research , Inverness , Florida , USA – name: 7 UOC Gastroenterologia , AO San Camillo Forlanini , Rome , Italy – name: 5 Department of Gastroenterology and Hepatology , University of Zürich , Zürich , Switzerland – name: 13 Department of Medicine I , Christian-Albrechts-University and University Hospital Schleswig-Holstein , Kiel , Germany – name: 6 Division of Gastroenterology, Rabin Medical Center , University of Tel-Aviv , Petah Tikva , Israel – name: 1 Gastrointestinal Immunopathology Lab and IBD Unit , Humanitas Clinical and Research Center and Humanitas University , Milan , Italy |
| Author_xml | – sequence: 1 givenname: Silvio surname: Danese fullname: Danese, Silvio email: sdanese@hotmail.com organization: Gastrointestinal Immunopathology Lab and IBD Unit, Humanitas Clinical and Research Center and Humanitas University, Milan, Italy – sequence: 2 givenname: Séverine surname: Vermeire fullname: Vermeire, Séverine email: sdanese@hotmail.com organization: Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium – sequence: 3 givenname: Paul surname: Hellstern fullname: Hellstern, Paul email: sdanese@hotmail.com organization: Nature Coast Clinical Research, Inverness, Florida, USA – sequence: 4 givenname: Remo surname: Panaccione fullname: Panaccione, Remo email: sdanese@hotmail.com organization: Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada – sequence: 5 givenname: Gerhard surname: Rogler fullname: Rogler, Gerhard email: sdanese@hotmail.com organization: Department of Gastroenterology and Hepatology, University of Zürich, Zürich, Switzerland – sequence: 6 givenname: Gerald surname: Fraser fullname: Fraser, Gerald email: sdanese@hotmail.com organization: Division of Gastroenterology, Rabin Medical Center, University of Tel-Aviv, Petah Tikva, Israel – sequence: 7 givenname: Anna surname: Kohn fullname: Kohn, Anna email: sdanese@hotmail.com organization: UOC Gastroenterologia, AO San Camillo Forlanini, Rome, Italy – sequence: 8 givenname: Pierre surname: Desreumaux fullname: Desreumaux, Pierre email: sdanese@hotmail.com organization: Lille University School of Medicine, University of Lille, Inserm U, Lille, France – sequence: 9 givenname: Rupert W orcidid: 0000-0001-5944-3488 surname: Leong fullname: Leong, Rupert W email: sdanese@hotmail.com organization: Inflammatory Bowel Diseases Service, Concord Hospital, Sydney, New South Wales, Australia – sequence: 10 givenname: Gail M surname: Comer fullname: Comer, Gail M email: sdanese@hotmail.com organization: Formerly of Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA – sequence: 11 givenname: Fabio surname: Cataldi fullname: Cataldi, Fabio email: sdanese@hotmail.com organization: Formerly of Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA – sequence: 12 givenname: Anindita surname: Banerjee fullname: Banerjee, Anindita email: sdanese@hotmail.com organization: Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA – sequence: 13 givenname: Mary K surname: Maguire fullname: Maguire, Mary K email: sdanese@hotmail.com organization: Worldwide Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA – sequence: 14 givenname: Cheryl surname: Li fullname: Li, Cheryl email: sdanese@hotmail.com organization: Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA – sequence: 15 givenname: Natalie surname: Rath fullname: Rath, Natalie email: sdanese@hotmail.com organization: Worldwide Research and Development, Pfizer Inc, Collegeville, Pennsylvania, USA – sequence: 16 givenname: Jean surname: Beebe fullname: Beebe, Jean email: sdanese@hotmail.com organization: Worldwide Research and Development, Pfizer Inc, Cambridge, Massachusetts, USA – sequence: 17 givenname: Stefan surname: Schreiber fullname: Schreiber, Stefan email: sdanese@hotmail.com organization: Department of Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29247068$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUtFuFCEUJaaN3VZ_wAdD4kt9QAeYAebFZLNW3aSpianPhJm507KysAJj3Dd_w9_zS2S7baN9MCYkBO45h3O55xgd-OABoWe0ekUpF6-vprzyjrCKSsJp3Qj2CM1oLRThTKkDNKt2lUbW7RE6TmlVVZVSLX2MjljLalkJNUPbT8YPYW0TDDhHaxwuZxw24IkzHTgM3zP4ZIPHKU_DFoexIMrKllifITqYvlhPxM1VFwrCeryI4dr_-vEz4aEomwT4dH7xdn5xeYaXNw8sly-foMPRuARPb_cT9Pnd2eXiAzn_-H65mJ-TrnSSiehbZjgAmKYVvKtGLmnfjYMUvex63lEOjWLUSAaDMqoRig4j0HFQNRuVkfwEvdnrbqZuDUMPPkfj9CbatYlbHYzVf1e8vdZX4ZsWireKsyJweisQw9cJUtblu3pwzngIU9K0lVIqVvO2QF88gK7CFH1pTzPa8GJUMFFQz_90dG_lbioFoPaAPoaUIoy6t9nkMoRi0DpNK70LgN4HQO8CoPcBKFT2gHqn_k8S2ZO69ep_8L8BfsvFZA |
| CitedBy_id | crossref_primary_10_1016_j_freeradbiomed_2020_10_029 crossref_primary_10_1038_s41586_021_03484_5 crossref_primary_10_3389_fimmu_2022_1055914 crossref_primary_10_1136_bmjgast_2018_000208 crossref_primary_10_3390_biom15010116 crossref_primary_10_1007_s00011_024_01854_z crossref_primary_10_4078_jrd_2020_27_3_128 crossref_primary_10_1016_j_immuni_2019_03_017 crossref_primary_10_3390_ijms24043957 crossref_primary_10_1159_000500721 crossref_primary_10_26442_00403660_2019_02_000155 crossref_primary_10_1016_j_gastha_2022_12_004 crossref_primary_10_1016_j_jaut_2023_103062 crossref_primary_10_3390_biomedicines12030685 crossref_primary_10_1016_j_coi_2021_04_007 crossref_primary_10_1080_00365521_2018_1447597 crossref_primary_10_2147_JPR_S424086 crossref_primary_10_3389_fimmu_2022_828219 crossref_primary_10_1016_j_celrep_2024_114736 crossref_primary_10_3390_biomedicines11112945 crossref_primary_10_3390_biomedicines13010247 crossref_primary_10_1093_ecco_jcc_jjz176 crossref_primary_10_1093_cei_uxae027 crossref_primary_10_1111_cts_13832 crossref_primary_10_1093_ecco_jcc_jjad027 crossref_primary_10_23736_S0394_9508_24_05697_3 crossref_primary_10_3390_ph15091080 crossref_primary_10_1016_j_mbplus_2022_100112 crossref_primary_10_1097_SHK_0000000000002051 crossref_primary_10_3390_molecules27248744 crossref_primary_10_3389_fimmu_2023_1158648 crossref_primary_10_1186_s12934_022_01873_7 crossref_primary_10_2147_JIR_S282600 crossref_primary_10_1177_20587392221076450 crossref_primary_10_3389_fmed_2021_644333 crossref_primary_10_1038_s41590_019_0415_0 crossref_primary_10_1016_j_jbc_2023_105343 crossref_primary_10_1097_MOG_0000000000000740 crossref_primary_10_1136_gutjnl_2020_322129 crossref_primary_10_1002_med_22022 crossref_primary_10_1111_cts_12850 crossref_primary_10_1002_jgh3_12362 crossref_primary_10_1016_j_jcmgh_2021_06_013 crossref_primary_10_3389_fimmu_2020_623691 crossref_primary_10_1007_s00109_020_01987_8 crossref_primary_10_1093_ecco_jcc_jjac021 crossref_primary_10_1093_mrcr_rxac090 crossref_primary_10_1016_j_cct_2022_106717 crossref_primary_10_1080_13543784_2023_2219386 crossref_primary_10_1016_j_intimp_2020_106464 crossref_primary_10_1016_j_prenap_2024_100038 crossref_primary_10_1038_s41575_021_00473_x crossref_primary_10_1038_s41577_024_01008_6 crossref_primary_10_4251_wjgo_v14_i3_547 crossref_primary_10_1016_j_intimp_2024_113544 crossref_primary_10_1056_NEJMe2301147 crossref_primary_10_1016_j_biopha_2022_114174 crossref_primary_10_3389_fnut_2021_739285 crossref_primary_10_3390_ph18010018 crossref_primary_10_1093_ecco_jcc_jjac150 crossref_primary_10_1002_jcla_23472 crossref_primary_10_1016_j_focha_2023_100498 crossref_primary_10_1016_j_phrs_2021_105918 crossref_primary_10_1111_cts_12849 crossref_primary_10_1016_j_cytox_2020_100029 crossref_primary_10_1128_spectrum_04370_22 crossref_primary_10_3389_fimmu_2023_1295230 crossref_primary_10_1016_j_ebiom_2021_103690 crossref_primary_10_1080_17568919_2024_2351293 crossref_primary_10_1007_s10875_023_01603_7 crossref_primary_10_1016_j_autrev_2023_103410 crossref_primary_10_3389_fphar_2021_651415 crossref_primary_10_1093_ibd_izae031 crossref_primary_10_2147_JIR_S492079 crossref_primary_10_2147_JIR_S449335 crossref_primary_10_1016_j_mehy_2020_110023 crossref_primary_10_1007_s10620_021_06831_8 crossref_primary_10_1016_j_bpg_2021_101763 crossref_primary_10_1080_14728222_2019_1677608 crossref_primary_10_1177_17562848241303651 crossref_primary_10_1155_2018_1924393 crossref_primary_10_1182_blood_2019000396 crossref_primary_10_3390_cells10010111 crossref_primary_10_3389_fmed_2025_1502189 crossref_primary_10_3389_fimmu_2021_669400 crossref_primary_10_1053_j_gastro_2020_04_012 crossref_primary_10_1136_gutjnl_2020_321269 crossref_primary_10_1016_j_cell_2020_03_007 crossref_primary_10_1177_2399369319863433 crossref_primary_10_3389_fphar_2019_00671 crossref_primary_10_1002_advs_202103035 crossref_primary_10_3390_ijms231810281 crossref_primary_10_3390_ijms26010121 crossref_primary_10_1097_FTD_0000000000000571 crossref_primary_10_12729_jbtr_2024_25_2_15 crossref_primary_10_3390_ijms23179897 crossref_primary_10_3389_fphar_2021_684486 crossref_primary_10_1016_j_ejphar_2021_174165 crossref_primary_10_1111_cts_13228 crossref_primary_10_1097_CM9_0000000000002792 crossref_primary_10_1371_journal_pcbi_1010112 crossref_primary_10_1093_ecco_jcc_jjad034 crossref_primary_10_3389_fphar_2021_654985 crossref_primary_10_1007_s12079_022_00695_x crossref_primary_10_1038_s41577_021_00540_z crossref_primary_10_3389_fimmu_2020_02174 crossref_primary_10_1016_j_cbi_2024_111013 crossref_primary_10_1080_14728214_2024_2303116 crossref_primary_10_1002_cncr_33125 crossref_primary_10_1007_s40291_024_00709_x crossref_primary_10_1186_s40164_024_00527_1 crossref_primary_10_3390_jcm11040994 crossref_primary_10_5217_ir_2023_00059 crossref_primary_10_2147_JIR_S409290 crossref_primary_10_1053_j_gastro_2021_03_030 crossref_primary_10_1080_14712598_2019_1652267 crossref_primary_10_1016_j_bmc_2020_115327 crossref_primary_10_1136_egastro_2023_100012 crossref_primary_10_1111_apt_15955 crossref_primary_10_1038_s41577_023_00856_y crossref_primary_10_3748_wjg_v25_i30_4125 crossref_primary_10_3748_wjg_v29_i7_1157 crossref_primary_10_1080_21645515_2018_1461297 crossref_primary_10_1053_j_gastro_2021_02_062 crossref_primary_10_3390_pathogens11010084 crossref_primary_10_3389_fimmu_2024_1412800 crossref_primary_10_3748_wjg_v27_i48_8242 crossref_primary_10_1002_ueg2_12305 crossref_primary_10_1016_j_semarthrit_2020_05_017 crossref_primary_10_2147_JIR_S422881 crossref_primary_10_1093_gastro_goad068 crossref_primary_10_1016_j_pharmthera_2021_107859 crossref_primary_10_14309_crj_0000000000001627 crossref_primary_10_1126_scitranslmed_abq4473 crossref_primary_10_23736_S1121_421X_19_02621_7 crossref_primary_10_1056_NEJMra1909094 crossref_primary_10_1080_14728222_2024_2306341 |
| Cites_doi | 10.1136/annrheumdis-2012-eular.724 10.1007/s10067-011-1827-x 10.1016/j.semarthrit.2014.07.006 10.1056/NEJMoa1602773 10.1053/j.gastro.2006.11.041 10.1111/apt.13445 10.2174/13894501113146660224 10.1016/S0140-6736(02)08512-4 10.1053/j.gastro.2004.01.012 10.1056/NEJMoa1215739 10.1056/NEJMoa067594 10.1136/annrheumdis-2016-209668 10.1053/j.gastro.2007.03.024 |
| ContentType | Journal Article |
| Copyright | Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2019 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2019 |
| Copyright_xml | – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. – notice: 2019 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:http://creativecommons.org/licenses/by-nc/4.0 – notice: Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. 2019 |
| DBID | 9YT ACMMV AAYXX CITATION NPM 3V. 7X7 7XB 88E 88I 8AF 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.1136/gutjnl-2017-314562 |
| DatabaseName | BMJ Open Access Journals (Free internet resource, activated by CARLI) BMJ Journals:Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection BMJ Journals ProQuest One ProQuest Central Korea ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection ProQuest Health & Medical Collection PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Central Student PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-3288 |
| EndPage | 48 |
| ExternalDocumentID | PMC6839832 29247068 10_1136_gutjnl_2017_314562 gutjnl |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- .55 .GJ .VT 08G 0R~ 18M 29I 2WC 354 39C 3O- 4.4 40O 53G 5GY 5VS 7X7 7~S 88E 88I 8AF 8F7 8FE 8FH 8FI 8FJ 8R4 8R5 9YT AAHLL AAKAS AAOJX AAUVZ AAWJN AAYEP ABAAH ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACMMV ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AI. AJYBZ ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DU5 DWQXO E3Z EBS EJD F5P FD8 FEDTE FYUFA GNUQQ GX1 H13 HAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IEA IH2 IHR INH INR IOF ITC J5H KQ8 L7B LK8 M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 TEORI TR2 UKHRP UYXKK V24 VH1 VM9 VVN W8F WH7 WOQ X7M YFH YOC YQY ZGI ZXP ZY1 AAYXX ACQHZ ADGHP AERUA CITATION PHGZM NPM PJZUB PPXIY PQGLB 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-b468t-6c92a3eeea5963b0f371cbfd76c7bc3b13e5821a72ed8a85681dfe1fd842f8a73 |
| IEDL.DBID | 9YT |
| ISSN | 0017-5749 1468-3288 |
| IngestDate | Thu Aug 21 14:03:19 EDT 2025 Thu Jul 10 19:00:18 EDT 2025 Fri Jul 25 11:53:32 EDT 2025 Mon Jul 21 06:06:30 EDT 2025 Thu Apr 24 22:51:13 EDT 2025 Tue Jul 01 02:49:03 EDT 2025 Thu Apr 24 23:05:37 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | inadequate response anti-IL6 antibody crohn’s disease anti-TNF |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b468t-6c92a3eeea5963b0f371cbfd76c7bc3b13e5821a72ed8a85681dfe1fd842f8a73 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0001-5944-3488 |
| OpenAccessLink | http://dx.doi.org/10.1136/gutjnl-2017-314562 |
| PMID | 29247068 |
| PQID | 2153582626 |
| PQPubID | 2041069 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6839832 proquest_miscellaneous_1977782439 proquest_journals_2153582626 pubmed_primary_29247068 crossref_citationtrail_10_1136_gutjnl_2017_314562 crossref_primary_10_1136_gutjnl_2017_314562 bmj_primary_10_1136_gutjnl_2017_314562 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-01 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Original article |
| PublicationTitle | Gut |
| PublicationTitleAlternate | Gut |
| PublicationYear | 2019 |
| Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Colombel, Sandborn, Rutgeerts 2007; 132 Targan, Feagan, Fedorak 2007; 132 Allocca, Jovani, Fiorino 2013; 14 Wallace, Strand, Merrill 2017; 76 Ito, Takazoe, Fukuda 2004; 126 Fogel, Sridharan, Li 2013; 71 Wilkins, Jarvis, Patel 2011; 84 Curtis, Perez-Gutthann, Suissa 2015; 44 Sandborn, Feagan, Rutgeerts 2013; 369 Gout, Ostör, Nisar 2011; 30 Ding, Hart, De Cruz 2016; 43 Hanauer, Feagan, Lichtenstein 2002; 359 Feagan, Sandborn, Gasink 2016; 375 Sandborn, Feagan, Stoinov 2007; 357 Wilkins (2020061508252953000_68.1.40.12) 2011; 84 Allocca (2020061508252953000_68.1.40.6) 2013; 14 2020061508252953000_68.1.40.10 2020061508252953000_68.1.40.11 Feagan (2020061508252953000_68.1.40.14) 2016; 375 2020061508252953000_68.1.40.3 2020061508252953000_68.1.40.2 2020061508252953000_68.1.40.5 Fogel (2020061508252953000_68.1.40.8) 2013; 71 2020061508252953000_68.1.40.4 2020061508252953000_68.1.40.13 2020061508252953000_68.1.40.1 2020061508252953000_68.1.40.7 2020061508252953000_68.1.40.9 |
| References_xml | – volume: 71 start-page: 680 issue: (Suppl.3) year: 2013 article-title: AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-eular.724 – volume: 30 start-page: 1471 year: 2011 article-title: Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review publication-title: Clin Rheumatol doi: 10.1007/s10067-011-1827-x – volume: 44 start-page: 381 year: 2015 article-title: Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2014.07.006 – volume: 375 start-page: 1946 year: 2016 article-title: Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1602773 – volume: 132 start-page: 52 year: 2007 article-title: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.11.041 – volume: 43 start-page: 30 year: 2016 article-title: Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.13445 – volume: 14 start-page: 1508 year: 2013 article-title: Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target publication-title: Curr Drug Targets doi: 10.2174/13894501113146660224 – volume: 359 start-page: 1541 year: 2002 article-title: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(02)08512-4 – volume: 126 start-page: 989 year: 2004 article-title: A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.01.012 – volume: 369 start-page: 711 year: 2013 article-title: Vedolizumab as induction and maintenance therapy for Crohn’s disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1215739 – volume: 357 start-page: 228 year: 2007 article-title: Certolizumab pegol for the treatment of Crohn’s disease publication-title: N Engl J Med doi: 10.1056/NEJMoa067594 – volume: 76 start-page: 534 year: 2017 article-title: Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-209668 – volume: 132 start-page: 1672 year: 2007 article-title: Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.03.024 – volume: 84 start-page: 1365 year: 2011 article-title: Diagnosis and management of Crohn’s disease publication-title: Am Fam Physician – ident: 2020061508252953000_68.1.40.13 doi: 10.1056/NEJMoa1215739 – ident: 2020061508252953000_68.1.40.2 doi: 10.1016/S0140-6736(02)08512-4 – volume: 84 start-page: 1365 year: 2011 ident: 2020061508252953000_68.1.40.12 article-title: Diagnosis and management of Crohn’s disease publication-title: Am Fam Physician – ident: 2020061508252953000_68.1.40.1 doi: 10.1053/j.gastro.2006.11.041 – volume: 375 start-page: 1946 year: 2016 ident: 2020061508252953000_68.1.40.14 article-title: Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1602773 – ident: 2020061508252953000_68.1.40.3 doi: 10.1056/NEJMoa067594 – volume: 14 start-page: 1508 year: 2013 ident: 2020061508252953000_68.1.40.6 article-title: Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target publication-title: Curr Drug Targets doi: 10.2174/13894501113146660224 – ident: 2020061508252953000_68.1.40.5 doi: 10.1111/apt.13445 – ident: 2020061508252953000_68.1.40.4 doi: 10.1053/j.gastro.2007.03.024 – ident: 2020061508252953000_68.1.40.7 doi: 10.1053/j.gastro.2004.01.012 – ident: 2020061508252953000_68.1.40.11 doi: 10.1007/s10067-011-1827-x – ident: 2020061508252953000_68.1.40.10 doi: 10.1016/j.semarthrit.2014.07.006 – ident: 2020061508252953000_68.1.40.9 doi: 10.1136/annrheumdis-2016-209668 – volume: 71 start-page: 680 issue: (Suppl.3) year: 2013 ident: 2020061508252953000_68.1.40.8 article-title: AB0724 Safety, pharmacokinetics, and pharmacodynamics of a human anti-IL6 monoclonal antibody PF-04236921 in healthy subjects publication-title: Ann Rheum Dis |
| SSID | ssj0008891 |
| Score | 2.6083884 |
| Snippet | ObjectiveNeutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in... Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn's disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD... |
| SourceID | pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 40 |
| SubjectTerms | Apoptosis Clinical medicine Clinical trials Crohn's disease Cytokines Employees Gangrene Gastroenterology Immunoglobulins Inflammation Inflammatory Bowel Disease Interleukin 6 Lupus Pain Patients R&D Remission Research & development Rheumatoid arthritis Rhinopharyngitis Studies Tumor necrosis factor Tumor necrosis factor-TNF Tumors |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagSIhLxT-BgoyEEAhZXcdZ2zmhVWnVReoeUCvtLfJf6JbFaXezB268Bq_HkzB2nMCCVCHlktiWk3xje2Y8_gahV1YWVFMjSeCSIQV3gqjSGDKqhbVWOVVHBr6TGT8-Kz7Ox_PkcFunsMp-TowTtW1M8JHvw9IUDnWC_v3-8oqErFFhdzWl0LiJbgXqshDSJeaDwRUieGg_E49FUfaHZhjf_7xpL_wSZIQGN10wA2Bx0V8vtpenf3TOv0Mn_1iLju6i3aRE4kmH-j10w_n76PZJ2iZ_gL59Ut42gKCzOKblwHCPQ6IsAqC7JY6u7-Anw5FeFjc11ICrXZDAH7Faus2XhSc8PtIN1Fh4fLBqzv3P7z_WOO3q4DeT2YfJ7PQQT2MH0-nbh-js6PD04JikHAtEF1y2hJsyV8w5p8YwFPWoZoIaXVvBjdCGacpcOEqrRO6sVDLQldna0RowzmupBHuEdnzj3ROEVa6lk5wZy3RBc6Op0sJJyhT0oE2Zodfwg6vLjkWjitYH41WHRBWQqDokMkR7DCqTmMpDwozltW3eDW3-p4e9Htoqjdl19VvCMvRyKAaswhaK8q7ZrCsK6jLoVKDFZehxJwlDdzmYsmLEZYbElowMFQKT93aJX5xHRm8OaipMrU-vf61n6A58Q9k5gPbQTrvauOegErX6RZT7X8ddC50 priority: 102 providerName: ProQuest |
| Title | Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II) |
| URI | https://gut.bmj.com/content/68/1/40.full https://www.ncbi.nlm.nih.gov/pubmed/29247068 https://www.proquest.com/docview/2153582626 https://www.proquest.com/docview/1977782439 https://pubmed.ncbi.nlm.nih.gov/PMC6839832 |
| Volume | 68 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bixMxFA57AfFFvDu6lggiig7bTKZJ5rHWLluhRZau1Kcht3G71oy00wff_Bv-PX-JJ5kLVhdZGBhmkkwg30nyJWfyHYSeG5ESRbSIvZZMnDLLY5lpHfcLboyRVhZBgW86Y6fn6fvFYLGH3lztwSeUHX_eVpduBWgSv6HmCfs-OgyiLN6eP827cVe08fEg44CnWXtE5spveBFgWHrwftBYVV8vd-elf8jm3_9M_jEJndxGtxr2iIc13HfQnnV30Y1p4x-_h76fSWdKgM4aHOJxYHjGPkJWDGjbFQ573n6DDAddWVwWkAOuahl74Yj1ym6_LF3MwitVQo6lw6N1eeF-_fi5wY07B78czt4NZ_MxnoQKJpNX99H5yXg-Oo2b4AqxSpmoYqazRFJrrRxAH1T9gnKiVWE401xpqgi1_gyt5Ik1QgqvU2YKSwoANymE5PQBOnCls48QlokSVjCqDVUpSbQiUnErCJVQg9JZhF5AA-ffavmMPCw7KMtrUHIPSl6DEiHSYpDrRqLcR8pY_bfM667MdWo4aqHNm866yYH1-PPCsLSL0LMuGbDyvhPpbLnd5AR4MpApoG8RelhbQldda0gR4js20mXwEt67KW55EaS8GfBTGFMfX7eFnqCb8JTVe0BH6KBab-1TYEWV6qF9vuC90CV66HA4mk4_wv3tePbh7Dc3dAqp |
| linkProvider | BMJ Publishing Group Ltd |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anQS8IO4UBhgJEAhZq-PUdh8QKlunlq0VmjZpb8G3sI6SjF6E9sbf4E_wo_glHOdSKEgTL5PyktiOE58vx-ccx98BeOpUzAyzigYuGRoLL6nuWEtbqXTOaa_TgoFvOBL9w_jdUftoDX7Ue2HCb5W1TiwUtcttiJFv4tQUNnWi_f3m9AsNWaPC6mqdQqOExa4_-4ou2-z1YBvl-yyKdnoHW31aZRWgJhZqToXtRJp773UbwWdaKZfMmtRJYaWx3DDuw-ZRLSPvlFaBoMulnqX4VlGqtOR430uwHnN0ZRqw_rY3er-_1P2qztGHur8t4069TYeLzY-L-Uk2QVSyEBgMjgdOZ-bzyeqE-I-V-_fPmn_MfjvX4VpltpJuibMbsOazm3B5WC3M34KzfZ25HDHjHSkSgRA8JyE1F0WY-Qkpgu0hMkcKQluSp1gDj_mYBsaK6cQvPo0zKopLJsca44xsTfPj7Oe37zNSrSORF93Rdnd00CODooPB4OVtOLyQ8b8DjSzP_D0gOjLKK8Gt4yZmkTVMG-kV4xp7MLbThOc4wMlpyduRFP4OF0kpiSRIIikl0QRWyyCxFTd6SNExObfNq2Wb_-lhoxZtUmmJWfIb0014sixGWYVFG535fDFLGBroaMWh3diEuyUSlt1F6DzLllBNkCsYWVYI3OGrJdn4uOAQF2gYozK_f_5jPYYr_YPhXrI3GO0-gKv4Pp0y_LQBjfl04R-iQTY3j6qvgMCHi_7wfgEau0tE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtMwGLbGkCZuEGcCA4wECISs1nFqOxcIVeuqhbEKoU3qXfAprKMko02Fdsdr8Co8Dk_C75ygIE3cTMpNYidO8n_2f7D9_Qg9sTKimhpJPJcMibgTRMXGkH4mrLXKqaxi4DuY8L2j6M10MN1AP9q9MH5ZZTsmVgO1LYyPkfdANflNnWB_97JmWcS70fj16RfiM0j5mdY2nUYNkX139hXct-WrZASyfhqG493DnT3SZBggOuKyJNzEoWLOOTUAIOp-xgQ1OrOCG6EN05Q5v5FUidBZqaQn67KZoxl8YZhJJRg89xK6LNiA-j4mpp2z51cP0VYLDEQUtxt2GO99XJUn-RzwSX2I0LsgoNj055N11fiPvfv3ss0_9OD4GrraGLB4WCPuOtpw-Q20ddBM0d9EZ-9VbgtAj7O4SgmC4Rz7JF0EAOfmuAq7-xgdrqhtcZFBDTjKGfHcFYu5W32a5YRXl3QBNWY53lkUx_nPb9-XuJlRws-Hk9FwcriLk6qBJHlxCx1dyN-_jTbzInd3EVahlk5yZizTEQ2NpkoLJylT0II2cYCewQ9OT2sGj7TyfBhPa0mkXhJpLYkA0VYGqWlY0n2yjvm597zs7vmfFrZb0abNeLFMf6M7QI-7YpCVn75RuStWy5SCqQ72HFiQAbpTI6FrLgQ3WvS5DJBYw0hXwbOIr5fks-OKTZyDiQzD-r3zX-sR2oLulr5NJvv30RX4nLiOQ22jzXKxcg_AMiv1w6oLYPThovvcL79CThQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomised+trial+and+open-label+extension+study+of+an+anti-interleukin-6+antibody+in+Crohn%E2%80%99s+disease+%28ANDANTE+I+and+II%29&rft.jtitle=Gut&rft.au=Danese%2C+Silvio&rft.au=Vermeire%2C+S%C3%A9verine&rft.au=Hellstern%2C+Paul&rft.au=Panaccione%2C+Remo&rft.date=2019-01-01&rft.issn=0017-5749&rft.eissn=1468-3288&rft.volume=68&rft.issue=1&rft.spage=40&rft.epage=48&rft_id=info:doi/10.1136%2Fgutjnl-2017-314562&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_gutjnl_2017_314562 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-5749&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-5749&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-5749&client=summon |